Matinas BioPharma Nanotechnologies, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2013-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.aquariusbio.com
Clinical Trials
8
Active:0
Completed:4
Trial Phases
3 Phases
Phase 1:2
Phase 2:5
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials
Phase 2
5 (62.5%)Phase 1
2 (25.0%)Phase 3
1 (12.5%)Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial 3
Phase 3
Not yet recruiting
- Conditions
- Cryptococcal Meningitis
- Interventions
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
- Target Recruit Count
- 270
- Registration Number
- NCT05541107
Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia
Phase 2
Completed
- Conditions
- Hypertriglyceridemia
- Interventions
- Drug: Omega 3 pentaenoic acid
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2022-03-04
- Lead Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT04177680
- Locations
- 🇺🇸
Matinas Investigational Site, Chicago, Illinois, United States
🇺🇸Matinas Investigational site, Richmond, Virginia, United States
Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)
- First Posted Date
- 2019-07-24
- Last Posted Date
- 2023-03-31
- Lead Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
- Target Recruit Count
- 178
- Registration Number
- NCT04031833
- Locations
- 🇺🇬
Infectious Disease Institute, Kampala, Uganda
Efficacy and Safety of Oral Encochleated Amphotericin B for the Treatment of Cryptococcal Infection
Phase 1
Withdrawn
- Conditions
- Cryptococcal Infections
- Interventions
- Drug: Encochleated Amphotericin B
- First Posted Date
- 2017-06-23
- Last Posted Date
- 2019-03-08
- Lead Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
- Registration Number
- NCT03196921
Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal Prophylaxis in Patients Undergoing Induction Chemotherapy for Acute Myelogenous and Lymphoblastic Leukaemia
Phase 2
Withdrawn
- Conditions
- Acute Myeloid LeukemiaAcute Lymphoblastic Leukemia
- Interventions
- Drug: Oral Encochleated Amphotericin B (CAMB)
- First Posted Date
- 2017-06-15
- Last Posted Date
- 2019-03-08
- Lead Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
- Registration Number
- NCT03187691
- Prev
- 1
- 2
- Next
News
No news found